MDT

86.39

-0.47%↓

A

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

MDT

86.39

-0.47%↓

A

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

MDT

86.39

-0.47%↓

A

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

MDT

86.39

-0.47%↓

A

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

MDT

86.39

-0.47%↓

A

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

Search

IQVIA Holdings Inc

Open

SectorHealthcare

169.1 -0.26

Overview

Share price change

24h

Current

Min

168.41

Max

171.11

Key metrics

By Trading Economics

Income

182M

514M

Sales

264M

4.4B

P/E

Sector Avg

21.753

56.063

Profit margin

11.778

Employees

93,000

EBITDA

1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+31.37% upside

Dividends

By Dow Jones

Next Earnings

5 May 2026

Market Stats

By TradingEconomics

Market Cap

-10B

29B

Previous open

169.36

Previous close

169.1

News Sentiment

By Acuity

50%

50%

170 / 349 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

IQVIA Holdings Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Apr 2026, 23:17 UTC

Earnings

Samsung Forecasts Record First-Quarter Operating Profit

6 Apr 2026, 23:00 UTC

Hot Stocks

Stocks to Watch: Health Insurers, Mawson, Owlet

6 Apr 2026, 22:13 UTC

Major Market Movers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 Apr 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 Apr 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 Apr 2026, 16:56 UTC

Major News Events

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 Apr 2026, 14:47 UTC

Major Market Movers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 Apr 2026, 00:00 UTC

Major News Events

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 Apr 2026, 23:58 UTC

Market Talk
Major News Events

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 Apr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 Apr 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 Apr 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 Apr 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6 Apr 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 Apr 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6 Apr 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6 Apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6 Apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 Apr 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 Apr 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 Apr 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 Apr 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 Apr 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6 Apr 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 Apr 2026, 18:36 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 Apr 2026, 17:59 UTC

Market Talk
Major News Events

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 Apr 2026, 17:13 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 Apr 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 Apr 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 Apr 2026, 14:59 UTC

Earnings

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Comparison

Price change

IQVIA Holdings Inc Forecast

Price Target

By TipRanks

31.37% upside

12 Months Forecast

Average 227.62 USD  31.37%

High 255 USD

Low 200 USD

Based on 16 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

14

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

150.68 / 153.45Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

170 / 349 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat